Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma

Pediatric Dermatology

Volumn 32, Issue 1, 2015, Pages 153-154

  West, Emily S ^a   Williams, Victoria L ^b   Morelli, Joseph G ^b,c  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VEMURAFENIB; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; INDOLE DERIVATIVE; SULFONAMIDE;

ADOLESCENT; ARTICLE; BRAIN STEM; CASE REPORT; CLINICAL FEATURE; FEMALE; FOLLOW UP; GLIOMA; HUMAN; HUMAN TISSUE; NEUTROPHILIC PANNICULITIS; PANNICULITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; ANTAGONISTS AND INHIBITORS; BRAIN STEM NEOPLASMS; CHEMICALLY INDUCED; NEUTROPHIL; PATHOLOGY;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN STEM NEOPLASMS; FEMALE; GLIOMA; HUMANS; INDOLES; NEUTROPHILS; PANNICULITIS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 84921881584     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/pde.12316     Document Type: Article

References (5)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
2. Rush S, Foreman N, Liu A,. Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol 2013; 31: e159-e160.
3. Huang V, Hepper D, Anadkat M, et al. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 2012; 148: 628-633.
4. Kim GH, Levy A, Compoginis G,. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol 2013; 40: 667-669.
5. Sutra-Loubet C, Carlotti A, Guillemette J, et al. Neutrophilic panniculitis. J Am Acad Dermatol 2004; 50: 280-285.